Lindbrook Capital’s Myriad Genetics MYGN Stock Holding History

Lindbrook Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$2.14K	Buy	241 +122	+103%	+$1.47K	﹤0.01%	2269
2024 Q4	$1.63K	Sell	119 -32	-21%	-$590	﹤0.01%	2363
2024 Q3	$4.14K	Buy	151 +3	+2%	+$81	﹤0.01%	2090
2024 Q2	$3.62K	Buy	148 +45	+44%	+$987	﹤0.01%	2136
2024 Q1	$2.2K	Hold	103	–	–	﹤0.01%	2210
2023 Q4	$1.97K	Buy	+103	New	+$1.78K	﹤0.01%	2266
2023 Q3	–	Sell	-17	Closed	-$394	–	2777
2023 Q2	$394	Sell	17 -57	-77%	-$1.24K	﹤0.01%	2556
2023 Q1	$1.72K	Buy	+74	New	+$1.5K	﹤0.01%	2305

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Lindbrook Capital's MYGN Position: Q1 2025 in Review

Lindbrook Capital increased its Myriad Genetics (MYGN) stake by 103% in Q1 2025, buying an estimated $1.47K and bringing the position to 241 shares worth $2.14K. The position accounts for ﹤0.01% of the portfolio, ranked #2269.

Lindbrook Capital first reported a position in MYGN in Q1 2023 and has held it in 8 quarters since. The position peaked at $4.14K in Q3 2024. 228 funds tracked by Wall St. Rank hold MYGN as of Q1 2025.

Lindbrook Capital held 241 shares of Myriad Genetics worth $2.14K as of Q1 2025.
Lindbrook Capital bought 122 Myriad Genetics shares in Q1 2025, an estimated $1.47K.
Myriad Genetics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2269 holding.
Lindbrook Capital first reported a position in Myriad Genetics in Q1 2023 and has held it in 8 quarters since.
Lindbrook Capital's Myriad Genetics position peaked at $4.14K in Q3 2024.
228 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.